Skip to main content
. Author manuscript; available in PMC: 2017 Jan 1.
Published in final edited form as: Methods Mol Biol. 2016;1364:183–196. doi: 10.1007/978-1-4939-3112-5_15

Fig. 2.

Fig. 2

Fig. 2

Human immune and leukemic cells efficiently internalize CpG-siRNA conjugates in vitro. (a) Targeted delivery of CpG-STAT3 siRNA into different primary human immune cells in vitro. Human PBMCs were incubated with fluorescently labeled CpG(A)-STAT3 siRNACy3 or unconjugated STAT3 siRNACy3 at 500 nM concentration for 1 h without any transfection reagents. Percentages of Cy3+ monocytes (CD14+), plasmacytoid dendritic cells (BDCA2+), B cells (CD19+), and T cells (CD3+) were assessed by flow cytometry. (b) CpG-siRNA internalization by human MM (KMS.11) and AML (MV4-11, KG1a) cells. Cells were incubated with 500 nM Cy3-labeled CpG-STAT3 siRNA for 1 h. The percentage of Cy3+ leukemic cells was analyzed by flow cytometry